The Enhancing Effects of Amastatin, Phosphoramidon and Captopril on the Potency of [Met5]-Enkephalin in Rat Vas Deferens Suying

Total Page:16

File Type:pdf, Size:1020Kb

The Enhancing Effects of Amastatin, Phosphoramidon and Captopril on the Potency of [Met5]-Enkephalin in Rat Vas Deferens Suying The Enhancing Effects of Amastatin, Phosphoramidon and Captopril on the Potency of [Met5]-Enkephalin in Rat Vas Deferens Suying CUI", Midori KAJIWARA,Kaori ISHII, KazukoAOKI, Junshi SAKAMOTO,Teruhiko MATSUMIYAand Tetsuo OKA* Departmentof Pharmacology,School of Medicine,Tokai University, Isehara259-11, Japan AcceptedMay 29, 1986 Abstract-The enkephalin-inactivating enzymes in rat vas deferens were studied by using the relatively specific inhibitor of each enzyme. The results showed that the rat vas deferens, like the other three preparations, guinea-pig ileum, mouse vas deferens and striatal membranes of guinea-pig brain, which had been investigated previously, contained three distinct enkephalin-hydrolyzing peptidases. Additionally, the enkephalin-hydrolyzing aminopeptidase, endopeptidase-24.11 and peptidyl dipeptidase A in rat vas deferens were found to be inhibited maximally with 1 IN of amastatin, 1 iiM of phosphoramidon and 1 ,IM of captopril, respectively. In contrast to these three enzymes, both L-tyrosyl-L-tyrosine-sensitive dipeptidyl aminopeptidase and D-phenylalanine-sensitive carboxypeptidase were suggested not to be involved significantly in the inactivation of exogenously given enkephalin in rat vas deferens. The characteristics of the enkephalin-degradative enzymes in rat vas deferens were discussed in terms of their similarities to and differences from those in the other preparations. Three enzymes, both bestatin and peptidases, since enkephalin remains intact amastatin-sensitive aminopeptidase, both almost totally after it is incubated with either thiorphan and phosphoramidon-sensitive ileal or striatal membrane fractions of guinea endopeptidase-24.11 ("enkephalinase", EC pig for 60 min at 37'C in the presence of 3.4.24.11), and captopril-sensitive peptidyl three peptidase inhibitors, amastatin, thior dipeptidase A (angiotensin I converting phan and captopril, although free tyrosine enzyme, kininase II, peptidyldipeptide hy and the Tyr-Gly-Gly fragment are produced drolase, EC 3.4.15.1), have been shown to when the incubation mixture does not play important roles in the inactivation of contain the peptidase inhibitor (3). exogenously given enkephalin in two in vitro On the other hand, the structure of phos isolated preparations, guinea-pig ileum (1) phoramidon-sensitive endopeptidase-24.1 1 and mouse vas deferens (2). Additionally, in the kidney has been reported to be slightly these three enzymes have been indicated to different from either that in the intestine (4) be located very close to opioid receptors (1, or that in the brain (5). Additionally, the lung 2). Moreover, enkephalin has been shown to and brain peptidyl dipeptidases have been be exclusively inactivated by these three shown to differ markedly in their substrate preference with the lung enzyme, failing to degrade substance K, while the brain enzyme ~r Present address: Department of Physiology , Institute of Clinical Research, China-Japan displays similar activity toward substance K Friendship Hospital, Heping North Street, Beijing, and substance P (6). Moreover, the inhibitory China. potency of /9-endorphin has been shown to * To whom reprint requests should be addressed . be significantly enhanced by the pretreatment of the mouse vas deferens with three deferens in order to examine the stabi ity of peptidase inhibitors, amastatin, captopril and the response of the preparation to an opioid phosphoramidon, while it is not augmented during the usual experimental period, since in both guinea-pig ileum and rat vas deferens it has been shown that the sensitivity to an by the same pretreatment (7). These four opioid of rabbit vas deferens was significantly reports suggest that the structure or the increased with the passage of time (9), while function of a particular peptidase in one that of guinea-pig ileum was not significantly preparation or tissue may not always be the changed during the usual experimental same as that in the other. period (1). The IC50 values of [Met5] In the present investigation, therefore, the enkephalin estimated initially and secondarily effect of peptidase inhibitor on the potency were significantly higher than those estimated of [Met5]-enkephalin in rat vas deferens was secondarily and thirdly, respectively (Table examined in order to e'ucidate whether or 1). On the other hand, the IC50 values not the enkephalin-hydrolyzing peptidase in estimated thirdly and fourthly were not sig rat vas deferens had the same characteristics nificantly different from those estimated as that in guinea-pig ileum (1) or mouse vas fourthly and fifthly, respectively (Table 1). deferens (2). Since the increased sensitivity of the pre paration to an opioid during the per od from Materials and Methods the initial to the third determination of the Chemicals: Gifts of compounds which IC50 value (Table 1) might be caused by were gratefully received were amastatin and the decreased activity of the enkephalin phosphoramidon from Dr. T. Aoyagi, Inst tute hydrolyzing enzymes during the identical of Microbial Chemistry (Tokyo), and captopril period, the IC50 value of [Met5]-enkephalin from Sankyo Company (Tokyo). [Met5] was then repeatedly estimated in the presence Enkephalin and D-phenylalanine were of three peptidase inhibitors, amastatin, purchased from Peptide Institute, Inc. captopril and phosphoramidon, at the final (Minoh), and L-tyrosyl-L-tyrosine was from concentration of 1 /tM each. The IC50 values Miles-Yeda, Ltd. (Israel). of [Met5]-enkephalin in the presence of In vitro isolated preparations: Male Wistar three peptidase inhibitors were also decreased rats weighing 300-500 g were used for this during the period from their initial to third study. The vasa deferentia from rats were determinations (Table 1), indicating the prepared and set up for electrical stimulation negative involvement of the peptidases in the as described previously (8). The % inhibition increased sensitivity of the preparation to of the stimulated muscle twitch produced by an opioid during the early phase of the [Met5]-enkephalin was plotted against the experiment. Since the results obtained in log concentration of the opioid to estimate the both the absence and the presence of the IC50 (concentration of the opioid to produce peptidase inhibitors showed that the response 50% inhibition of the twitch). When the of the preparation to an opioid was not effect of peptidase inhibitors on the IC50 significantly changed during the period from value of [Met5]-enkephalin was studied, the third to the fifth estimation of the IC50 they were given at least ten minutes before value, the following experiments on the effect the enkephalin administration. The % of the peptidase inhibitor on the potency of difference shown in the table was calculated [Met5]-enkephalin in rat vas deferens were as described previously (2). The significance carried out during the equivalent period from of % differences between IC50 values of the third to the fifth estimation of the IC50 two adjacent groups shown in the table was value. determined by the paired Student's t-test. Enhanced effect of the peptidase inhibitor on the potency of [Met5]-enkephalin: Results [Met5]-Enkephalin had been shown to be The control experiment: The IC50 value of hydrolyzed by three distinct enzymes in [Met5]-enkephalin was repeatedly estimated several preparations such as guinea-pig for five times in six preparations of rat vas ileum (1), mouse vas deferens (2), and both Table 1. The repeated estimation of the IC50 values of [Met5]-enkephalin in either the presence or the absence of the mixture of peptidase inhibitors The approximate interval of each [Met5]-enkephalin administration was 30 min. Each value represents the mean±S.E. of 6 experiments. :,The mixture of three peptidase inhibitors, amastatin, captopril and phosphoramidon, was given 10 min before the enkephalin administration at the final concentration of 1 fiM each. ***P<0.01. Table 2. Enhancing effect of amastatin on the inhibitory potency of [Met5]-enkephalin in rat vas deferens pretreated with both phosphoramidon and captopril The mixture of two peptidase inhibitors, phosphoramidon and captopril, was added 10 min before the enkephalin administration at the final concentration of 1 ,uM each. Amastatin was given immediately after the mixture administration. Each value represents the mean±S.E. of 4 experiments. ***P<0.01. ileal and striatal membrane fractions of of 1 ,uM of amastatin was not significantly guinea-pig (3). Therefore, the presence of different from that of 2 pM of amastatin, but the enzyme with low enkephalin-hydrolyzing significantly lower than that of 0.1 uM of activity was sometimes difficult to detect amastatin (Table 2). This implied that the when the residual enzyme with high enkephalin-hydrolyzing aminopeptidase in rat enkephalin-hydrolyzing activity was not vas deferens was inhibited maximally with inhibited (3). Then, when the enkephalin amastatin at the final concentration of 1 ,uM, hydrolyzing ability of a particular enzyme being consistent with the previous findings among three enzymes was examined, the obtained with guinea-pig ileum (1) and residual two enzymes were inhibited in mouse vas deferens (2). However, Corbett advance in the present study. et al. (10) and McKnight et al. (11) have Initially, the effect of amastatin, an amino suggested that the susceptibility to bestatin, peptidase inhibitor, on the inhibitory potency another aminopeptidase inhibitor, of the of [Met5]-enkephalin in the rat vas deferens enkephalin-hydrolyzing
Recommended publications
  • Analytical Performance of an Immunoassay to Measure Proenkephalin ⁎ Leslie J
    Clinical Biochemistry xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Clinical Biochemistry journal homepage: www.elsevier.com/locate/clinbiochem Analytical performance of an immunoassay to measure proenkephalin ⁎ Leslie J. Donatoa, ,Jeffrey W. Meeusena, John C. Lieskea, Deborah Bergmannc, Andrea Sparwaßerc, Allan S. Jaffea,b a Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States b Division of Cardiology, Mayo Clinic, Rochester, MN 55905, United States c Sphingotec GmbH, Hennigsdorf, Germany ARTICLE INFO ABSTRACT Keywords: Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature Biomarkers pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 Proenkephalin (PENK), a stable peptide formed concomitantly with mature enkephalins. Enkephalin Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich im- Pro-enkephalin munoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from penKid healthy individuals to establish a reference interval and in patients with varied levels of kidney function and Assay validation comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quanti- tation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days.
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Enkephalin Degradation in Serum of Patients with Inflammatory Bowel Diseases
    Pharmacological Reports 71 (2019) 42–47 Contents lists available at ScienceDirect Pharmacological Reports journal homepage: www.elsevier.com/locate/pharep Original article Enkephalin degradation in serum of patients with inflammatory bowel diseases a, a b Beata Wilenska *, Dagmara Tymecka , Marcin Włodarczyk , b c Aleksandra Sobolewska-Włodarczyk , Maria Wisniewska-Jarosinska , d e b a,d, Jolanta Dyniewicz , Árpád Somogyi , Jakub Fichna , Aleksandra Misicka * a Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warszawa, Poland b Department of Biochemistry, Medical University of Lodz, Łódz, Poland c Department of Gastroenterology, Medical University of Lodz, Łódz, Poland d Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Science, Warszawa, Poland e Campus Chemical Instrumentation Centre (CCIC), The Ohio State University, Columbus, OH, USA A R T I C L E I N F O A B S T R A C T Article history: Background: Inflammatory bowel diseases (IBD) are a group of chronic and recurrent gastrointestinal Received 18 April 2018 disorders that are difficult to control. Recently, a new IBD therapy based on the targeting of the Received in revised form 10 June 2018 endogenous opioid system has been proposed. Consequently, due to the fact that endogenous Accepted 1 August 2018 enkephalins have an anti-inflammatory effect, we aimed at investigating the degradation of serum Available online 2 August 2018 enkephalin (Met- and Leu-enkephalin) in patients with IBD. Methods: Enkephalin degradation in serum of patients with IBD was characterized using mass Keywords: spectrometry methods. Calculated half-life (T1/2) of enkephalins were compared and correlated with the Inflammatory bowel diseases disease type and gender of the patients.
    [Show full text]
  • PRODUCT INFORMATION Spinorphin Item No
    PRODUCT INFORMATION Spinorphin Item No. 29914 NH CAS Registry No.: 137201-62-8 Formal Name: L-leucyl-L-valyl-L-valyl-L-tyrosyl-L- O H O N prolyl-L-tryptophyl-L-threonine N OH O N H Synonyms: Leu-Val-Val-Tyr-Pro-Trp-Thr, O OH H LVVYPWT O O N MF: C45H64N8O10 N N O FW: 877.0 H H NH2 Purity: ≥95% UV/Vis.: λmax: 222 nm Supplied as: A crystalline solid Storage: -20°C OH Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Spinorphin is supplied as a crystalline solid. A stock solution may be made by dissolving the spinorphin in the solvent of choice, which should be purged with an inert gas. Spinorphin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of spinorphin in these solvents is approximately 30 mg/ml. Description Spinorphin is a heptapeptide inhibitor of the enkephalin-degrading enzymes aminopeptidase, dipeptidyl aminopeptidase, angiotensin-converting enzyme (ACE), and enkephalinase (IC50s = 3.3, 1.4, 2.4, and 10 µg/ml, respectively, for monkey brain enzymes).1 It is selective for these enzymes over human serum aminopeptidase A (IC50 = >100 µg/ml), as well as porcine kidney aminopeptidase B, aminopeptidase M, dipeptidyl peptidase 1 (DPP-1), DPP-2, DPP-3, and DPP-4 (IC50s = >55 µg/ml for all). Spinorphin inhibits chemotaxis, production of reactive oxygen species (ROS), and exocytosis of glucuronidase and collagenase in polymorphonuclear neutrophils (PMNs). It potentiates enkephalin-induced action potentials in rat hippocampal slices.
    [Show full text]
  • Antitumor Activity of Actinonin in Vitro and in Vivo
    Vol. 4, 171-176, January 1998 Clinical Cancer Research 171 Antitumor Activity of Actinonin in Vitro and in Vivo Yang Xu, Lawrence T. Lai, Janice L. Gabrilove, 8), mye!oid and monocytic cells, and most myeloblastic leuke- and David A. Scheinberg’ mias as well as on cells and tissues outside the hematopoietic system including fibroblasts, intestinal epithelium, renal tubular Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 epithelium, and synaptic membranes of the central nervous system (I ). APN occurs as a homodimer, and the molecule is a 150-kDa, transmembrane glycoprotein with an intracellular ABSTRACT amino terminus (1). F23, an antihuman CD13/APN mAb, is able Actinonin, an antibiotic and CD13/aminopeptidase N to completely block the active site of the enzyme (9). (APN) inhibitor, has been shown to be cytotoxic to tumor Bestatin, a CD 1 3/APN inhibitor, was examined in preclin- cell lines in vitro. We investigated the antiproliferative ef- ical and clinical studies; bestatin could inhibit lymph node fects of actinonin on human and murine leukemia and lym- metastasis of P388 leukemia in mice (10) and was used in phoma cells. Actinonin inhibited growth of NB4 and HL6O clinical trials in malignant skin tumors (1 1), in head and neck human cell lines and AKR mouse leukemia cells in vitro with cancer (12), in esophageal cancer (13), and in gynecologic an IC50 of about 2-S g/ml. The inhibitory effect on CD13- tumors (14). High doses of bestatin resulted in the significant positive cells was not blocked by pretreatment with the inhibition of preexisting experimental and spontaneous metas- anti-CD13/APN monoclonal antibody F23, which binds with tasis in mice (15).
    [Show full text]
  • Neprilysin Controls the Synaptic Activity of Neuropeptides in the Intercalated Cells of the Amygdala
    Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted. The final version may differ from this version. Neprilysin controls the synaptic activity of neuropeptides in the intercalated cells of the amygdala Authors: Gregoriou GC, Patel SD, Winters BL, Bagley EE Primary laboratory of origin: Discipline of Pharmacology & Charles Perkins Centre, Charles Perkins Centre D17, Downloaded from University of Sydney, Camperdown, NSW, 2006, Australia. molpharm.aspetjournals.org at ASPET Journals on October 1, 2021 1 Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted. The final version may differ from this version. Running title: Neuropeptides degradation in the amygdala Corresponding author: Elena Bagley Address: Discipline of Pharmacology & Charles Perkins Centre, Charles Perkins Centre D17, University of Sydney, Camperdown, NSW, 2006, Australia. Telephone: 61 2 93514895 Fax: N/A E-mail: [email protected] Number of pages: 31 Downloaded from Number of figures: 3 Number of references: 56 Words in abstract: 245 molpharm.aspetjournals.org Words in introduction: 486 Words in discussion: 844 Abbreviations: at ASPET Journals on October 1, 2021 ACE: angiotensin-converting enzyme ACSF: artificial cerebrospinal fluid APN: aminopeptidase N BLA: basolateral amygdala CNS: central nervous system DOR: δ-opioid receptor EPSC: excitatory post‐synaptic currents MOR: µ-opioid receptor met-enk: methione enkephalin NEP: neprilysin N/OFQ: Nociceptin/Orphanin FQ PI: peptidase inhibitors PPR: paired pulse ratio 2 Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted.
    [Show full text]
  • The Inhibition of Enkephalin Catabolism by Dual Enkephalinase Inhibitor: a Novel Possible Therapeutic Approach for Opioid Use Disorders
    Alvarez-Perez Beltran (Orcid ID: 0000-0001-8033-3136) Maldonado Rafael (Orcid ID: 0000-0002-4359-8773) THE INHIBITION OF ENKEPHALIN CATABOLISM BY DUAL ENKEPHALINASE INHIBITOR: A NOVEL POSSIBLE THERAPEUTIC APPROACH FOR OPIOID USE DISORDERS ALVAREZ-PEREZ Beltran1*, PORAS Hervé 2*, MALDONADO Rafael1 1 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, c/Dr Aiguader 88, 08003 Barcelona, Spain, 2 Pharmaleads, Paris BioPark, 11 Rue Watt, 75013 Paris, France *Both authors participated equally to the manuscript Correspondence: Rafael Maldonado, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), c/Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: [email protected] ABSTRACT Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual Enkephalinase Inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggest that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • Citation Classics and Trends in the Field of Opioids: a Bibliometric Analysis
    Open Access Original Article DOI: 10.7759/cureus.5055 Citation Classics and Trends in the Field of Opioids: A Bibliometric Analysis Hira F. Akbar 1 , Khadijah Siddiq 2 , Salman Nusrat 3 1. Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, PAK 2. Internal Medicine, Civil Hospital Karachi, Dow University of Health Sciences, Karachi, PAK 3. Gasteroenterology, University of Oklahoma Health Sciences Center, Oklahoma City, USA Corresponding author: Hira F. Akbar, [email protected] Abstract Introduction Bibliometric analysis is one of the emerging and latest statistical study type used to examine and keep a systemic record of the research done on a particular topic of a certain field. A number of such bibliometric studies are conducted on various topics of the medical science but none existed on the vast topic of pharmacology - opioids. Hence, we present a bibliometric analysis of the ‘Citation Classics’ of opioids. Method The primary database chosen to extract the citation classics of opioids was Scopus. Top 100 citation classics were arranged according to the citation count and then analyzed. Results The top 100 citation classics were published between 1957 and 2013, among which seventy-two were published from 1977 to 1997. Among all nineteen countries that contributed to these citation classics, United States of America alone produced sixty-three classics. The top three journals of the list were multidisciplinary and contained 36 citation classics. Endogenous opioids were the most studied (n=35) class of opioids among the citation classes and the most studied subject was of the neurosciences. Conclusion The subject areas of neurology and analgesic aspects of opioids are well established and endogenous and synthetic opioids were the most studied classes of opioids.
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Enkephalin After Peptidase Inhibition
    J Pharmacol Sci 106, 295 – 300 (2008)2 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Great Increase in Antinociceptive Potency of [Leu5]Enkephalin After Peptidase Inhibition Kazuhito Akahori1, Kenya Kosaka1, Xing Lu Jin1, Yoshiharu Arai1, Masanobu Yoshikawa1, Hiroyuki Kobayashi1, and Tetsuo Oka1,* 1Department of Clinical Pharmacology, School of Medicine, Tokai University, Isehara 259-1143, Japan Received August 9, 2007; Accepted December 19, 2007 Abstract. Previous in vitro studies have shown that the degradation of [Leu5]enkephalin during incubation with cerebral membrane preparations is almost completely prevented by a mixture of three peptidase inhibitors: amastatin, captopril, and phosphoramidon. The present in vivo study shows that the inhibitory effect of [Leu5]enkephalin administered intra-third-ventricularly on the tail-flick response was increased more than 500-fold by the intra-third-ventricular pretreatment with the three peptidase inhibitors. The antinociceptive effect produced by the [Leu5]enkephalin in rats pretreated with any combination of two peptidase inhibitors was significantly smaller than that in rats pretreated with the three peptidase inhibitors, indicating that any residual single peptidase could inactivate significant amounts of the [Leu5]enkephalin. The present data, together with those obtained from previous studies, clearly demonstrate that amastatin-, captopril-, and phosphoramidon-sensitive enzymes play important roles in the inactivation of short endogenous opioid
    [Show full text]
  • New Trends in the Development of Opioid Peptide Analogues As Advanced Remedies for Pain Relief
    Current Topics in Medicinal Chemistry 2004, 4, 19-38 19 New Trends in the Development of Opioid Peptide Analogues as Advanced Remedies for Pain Relief Luca Gentilucci* Dipartimento di Chimica “G. Ciamician”, via Selmi 2, Università degli Studi di Bologna, 40126- Bologna, Italy Abstract: The search for new peptides to be used as analgesics in place of morphine has been mainly directed to develop peptide analogues or peptidomimetics having higher biological stability and receptor selectivity. Indeed, most of the alkaloid opioid counterindications are due to the scarce stability and the contemporary activation of different receptor types. However, the development of several extremely stable and selective peptide ligands for the different opioid receptors, and the recent discovery of the m-receptor selective endomorphins, rendered this search less fundamental. In recent years, other opioid peptide properties have been investigated in the search for new pharmacological tools. The utility of a drug depends on its ability to reach appropriate receptors at the target tissue and to remain metabolically stable in order to produce the desired effect. This review deals with the recent investigations on peptide bioavailability, in particular barrier penetration and resistance against enzymatic degradation; with the development of peptides having activity at different receptors; with chimeric peptides, with propeptides, and with non-conventional peptides, lacking basic pharmacophoric features. Key Words. Opioid peptide analogues; opioid receptors; pain; antinociception; peptide stability; bioavailability. INTRODUCTION. OPIOID PEPTIDES, RECEPTORS, receptor interaction by structure-function studies of AND PAIN recombinant receptors and chimera receptors [7,8]. Experiments performed on mutant mice gave new The endogenous opioid peptides have been studied information about the mode of action of opioids, receptor extensively since their discovery aiming to develop effective heterogeneity and interactions [9].
    [Show full text]
  • Małgorzata Katarzyna Sobocińska Faculty of Chemistry Department of Molecular Biotechnology Laboratory of Chemistry of Biological Macromolecules
    Małgorzata Katarzyna Sobocińska Faculty of Chemistry Department of Molecular Biotechnology Laboratory of Chemistry of Biological Macromolecules Supervisor: Dr. hab. Elżbieta Kamysz, UG Prof. SUMMARY OF DOCTORAL DISSERTATION “Synthesis and biological studies of endogenous enkephalinase inhibitors and their analogues as potential therapeutic substances in therapy of inflammatory bowel disease and visceral pain” Pharmacological treatment and/or maintenance of remission in inflammatory bowel disease (IBD) which includes Crohn’s disease (CD) and ulcerative colitis (UC) is currently one of the biggest challenges in the field of gastroenterology. The main goal in anti-IBD therapy includes management of inflammation and alleviation of other clinical symptoms like intestinal motility disorder or visceral pain. One of the recent trends in the research of new forms of IBD therapy focuses on the endogenous opioid system. Endogenous opioid peptides such as enkephalins (Met-enkephalin and Leu-enkephalin) participate in the antinociception [1], regulation of gastrointestinal motility [2], regulation of the immune system [3, 4], cardiovascular system [5, 6] anti-inflammatory, hormonal and behavioural responses [7,8]. The action of endogenous opioids in the living organism is strongly regulated by their metabolism and the half-life of enkephalins in the human plasma can be measured within minutes [9], which significantly hampers their pharmacological application. Aminopeptidase N (APN), neutral endopeptidase (NEP), dipeptidyl peptidase III (DPP III) and angiotensin- converting enzyme (ACE) are the major enkephalin-degrading enzymes. These proteases are widely distributed in the human body and are significantly involved in physiological modulation and pathophysiological processes in the gastrointestinal tract [10]. Rat sialorphin (Gln-His-Asn-Pro-Arg), human opiorphin (Gln-Arg-Phe-Ser-Arg) and bovine spinorphine (Leu-Val-Val-Tyr-Pro-Trp-Thr) are endogenous inhibitors of enkephalin-degrading enzymes.
    [Show full text]